RU2006113366A - Терапевтическое лечение - Google Patents
Терапевтическое лечение Download PDFInfo
- Publication number
- RU2006113366A RU2006113366A RU2006113366/15A RU2006113366A RU2006113366A RU 2006113366 A RU2006113366 A RU 2006113366A RU 2006113366/15 A RU2006113366/15 A RU 2006113366/15A RU 2006113366 A RU2006113366 A RU 2006113366A RU 2006113366 A RU2006113366 A RU 2006113366A
- Authority
- RU
- Russia
- Prior art keywords
- combination according
- prevention
- atherosclerosis
- treatment
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Materials For Medical Uses (AREA)
Claims (11)
1. Комбинация, содержащая кандесартан или его фармацевтически приемлемую соль и розувастатин или его фармацевтически приемлемую соль, для предупреждения или лечения атеросклероза.
2. Фармацевтическая композиция, содержащая комбинацию по п.1 вместе с фармацевтически приемлемым разбавителем или носителем, для применения в предупреждении или лечении атеросклероза.
3. Фармацевтическая композиция, содержащая комбинацию по п.1 вместе с фармацевтически приемлемым разбавителем или носителем, для применения в предупреждении сердечно-сосудистых событий.
4. Комбинация по п.1 для применения в изготовлении лекарства для предупреждения или лечения атеросклероза.
5. Комбинация по п.1 для применения в изготовлении лекарства для предупреждения сердечно-сосудистых событий.
6. Комбинация по п.1 для применения в качестве лекарственного средства для предупреждения или лечения атеросклероза.
7. Комбинация по п.1 для применения в качестве лекарственного средства для предупреждения сердечно-сосудистых событий.
8. Способ предупреждения или лечения атеросклероза у теплокровного животного, например человека, включающий введение комбинации по п.1.
9. Способ предупреждения сердечно-сосудистых событий у теплокровного животного, например человека, включающий введение комбинации по п.1.
10. Набор, включающий комбинацию по п.1, возможно, с инструкциями по применению в предупреждении или лечении атеросклероза.
11. Комбинация по п.1, в которой кандесартан находится в форме кандесартана цилексетила.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0322552.1 | 2003-09-26 | ||
| GBGB0322552.1A GB0322552D0 (en) | 2003-09-26 | 2003-09-26 | Therapeutic treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006113366A true RU2006113366A (ru) | 2007-11-10 |
| RU2358737C2 RU2358737C2 (ru) | 2009-06-20 |
Family
ID=29286881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006113366/15A RU2358737C2 (ru) | 2003-09-26 | 2004-09-22 | Терапевтическое лечение |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7932263B2 (ru) |
| EP (1) | EP1673091B1 (ru) |
| JP (1) | JP4841433B2 (ru) |
| KR (1) | KR101129767B1 (ru) |
| CN (1) | CN100515421C (ru) |
| AT (1) | ATE451103T1 (ru) |
| AU (1) | AU2004275567B2 (ru) |
| BR (1) | BRPI0414724A (ru) |
| CA (1) | CA2540102C (ru) |
| CY (1) | CY1109814T1 (ru) |
| DE (1) | DE602004024555D1 (ru) |
| DK (1) | DK1673091T3 (ru) |
| ES (1) | ES2336450T3 (ru) |
| GB (1) | GB0322552D0 (ru) |
| HK (1) | HK1090553A1 (ru) |
| HR (1) | HRP20100080T1 (ru) |
| IL (1) | IL174536A (ru) |
| IS (1) | IS2729B (ru) |
| MX (1) | MXPA06003353A (ru) |
| NO (1) | NO335813B1 (ru) |
| NZ (1) | NZ546162A (ru) |
| PL (1) | PL1673091T3 (ru) |
| PT (1) | PT1673091E (ru) |
| RU (1) | RU2358737C2 (ru) |
| SG (1) | SG145773A1 (ru) |
| SI (1) | SI1673091T1 (ru) |
| UA (1) | UA90249C2 (ru) |
| WO (1) | WO2005030215A2 (ru) |
| ZA (1) | ZA200602433B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| WO2007051007A2 (en) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
| EP2483401B1 (en) * | 2009-09-29 | 2017-06-21 | Butamax (TM) Advanced Biofuels LLC | Improved yeast production host cells |
| US20120239131A1 (en) * | 2011-03-15 | 2012-09-20 | Medtronic Vascular, Inc. | Methods and apparatus for treatment of aneurysmal tissue |
| ES2622893T3 (es) * | 2011-12-09 | 2017-07-07 | Tratamiento de la pared arterial mediante la combinación de un inhibidor del SRAA y un inhibidor de la HMG-CoA reductasa | |
| CN103479627A (zh) * | 2013-05-16 | 2014-01-01 | 武汉光谷百桥国际生物科技有限公司 | 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用 |
| KR101771766B1 (ko) | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제 |
| CN109996545A (zh) * | 2016-11-15 | 2019-07-09 | 株式会社Lg化学 | 用于治疗2型糖尿病和糖尿病性血脂异常的药物复合物 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5703110A (en) * | 1990-04-27 | 1997-12-30 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
| US6004989A (en) * | 1990-04-27 | 1999-12-21 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
| CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
| US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
| CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| JP3883205B2 (ja) * | 1994-03-29 | 2007-02-21 | メルク エンド カンパニー インコーポレーテッド | アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療 |
| FR2741620B1 (fr) | 1995-11-28 | 1997-12-26 | Oreal | Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline |
| EP0914158B2 (en) | 1996-04-05 | 2006-01-25 | Takeda Chemical Industries, Ltd. | Pharmaceutical combination containing a compound having angiotensin ii antagonistic activity and a compound which increases the insulin-sensitivity |
| ES2232873T3 (es) * | 1996-07-15 | 2005-06-01 | Sankyo Company Limited | Composiciones farmaceuticas que comprenden el cs-866 y otros agentes que mejoran la resistencia a la insulina y su uso para el tratamiento de la arterosclerosis y el xantoma. |
| JPH1081633A (ja) | 1996-07-16 | 1998-03-31 | Sankyo Co Ltd | 医薬組成物 |
| AP1207A (en) | 1997-08-29 | 2003-09-20 | Pfizer Prod Inc | Combination therapy. |
| GT199800126A (es) | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| GB9900339D0 (en) | 1999-01-09 | 1999-02-24 | Zeneca Ltd | Chemical compounds |
| AR022462A1 (es) | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
| GB0000710D0 (en) | 1999-02-06 | 2000-03-08 | Zeneca Ltd | Drug combination |
| GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| GB9903472D0 (en) | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| CN1353706A (zh) | 1999-04-13 | 2002-06-12 | 巴斯福股份公司 | 整合素受体配体 |
| UA77151C2 (en) | 1999-08-30 | 2006-11-15 | Sanofi Aventis Deutschland | Use of ramipril for prevention of cardiovascular events |
| CA2381926A1 (en) | 1999-08-31 | 2001-03-08 | Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| WO2001072706A1 (en) | 2000-03-28 | 2001-10-04 | Biocon India Limited | Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
| AR030414A1 (es) | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
| GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| SK14642002A3 (sk) * | 2000-04-12 | 2003-05-02 | Novartis Ag | Kombinované farmaceutické prostriedky obsahujúce antagonistu AT1-receptora a/alebo inhibítor HMG-CoA reduktázy a/alebo ACE inhibítor |
| US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| JP2002145770A (ja) * | 2000-08-30 | 2002-05-22 | Sankyo Co Ltd | 心不全の予防又は治療のための医薬組成物 |
| CA2420844A1 (en) | 2000-08-30 | 2003-02-28 | Sankyo Company, Limited | Medicinal compositions for preventing or treating heart failure |
| GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
| ATE331512T1 (de) * | 2001-01-26 | 2006-07-15 | Schering Corp | Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie |
| NZ545332A (en) * | 2001-01-26 | 2007-09-28 | Schering Corp | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| WO2002095402A2 (en) * | 2001-04-18 | 2002-11-28 | Mcgill University | Individualization of therapy with hyperlipidemia agents |
| SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Astrazeneca Ab | Rosuvastatin in pre demented states |
| ATE433978T1 (de) * | 2003-04-29 | 2009-07-15 | Pfizer Ltd | 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| GB0321827D0 (en) | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| JP2005126338A (ja) | 2003-10-21 | 2005-05-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | 心不全治療剤 |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| US20060078615A1 (en) | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
-
2003
- 2003-09-26 GB GBGB0322552.1A patent/GB0322552D0/en not_active Ceased
-
2004
- 2004-09-22 AT AT04768663T patent/ATE451103T1/de active
- 2004-09-22 CN CNB2004800348230A patent/CN100515421C/zh not_active Expired - Lifetime
- 2004-09-22 ES ES04768663T patent/ES2336450T3/es not_active Expired - Lifetime
- 2004-09-22 MX MXPA06003353A patent/MXPA06003353A/es active IP Right Grant
- 2004-09-22 KR KR1020067007973A patent/KR101129767B1/ko not_active Expired - Fee Related
- 2004-09-22 PT PT04768663T patent/PT1673091E/pt unknown
- 2004-09-22 EP EP04768663A patent/EP1673091B1/en not_active Expired - Lifetime
- 2004-09-22 PL PL04768663T patent/PL1673091T3/pl unknown
- 2004-09-22 JP JP2006527488A patent/JP4841433B2/ja not_active Expired - Lifetime
- 2004-09-22 WO PCT/GB2004/004120 patent/WO2005030215A2/en active Application Filing
- 2004-09-22 SI SI200431337T patent/SI1673091T1/sl unknown
- 2004-09-22 CA CA2540102A patent/CA2540102C/en not_active Expired - Fee Related
- 2004-09-22 AU AU2004275567A patent/AU2004275567B2/en not_active Ceased
- 2004-09-22 US US10/573,353 patent/US7932263B2/en active Active
- 2004-09-22 RU RU2006113366/15A patent/RU2358737C2/ru not_active IP Right Cessation
- 2004-09-22 UA UAA200603434A patent/UA90249C2/ru unknown
- 2004-09-22 SG SG200806320-8A patent/SG145773A1/en unknown
- 2004-09-22 DE DE602004024555T patent/DE602004024555D1/de not_active Expired - Lifetime
- 2004-09-22 BR BRPI0414724-3A patent/BRPI0414724A/pt active Search and Examination
- 2004-09-22 NZ NZ546162A patent/NZ546162A/en not_active IP Right Cessation
- 2004-09-22 DK DK04768663.9T patent/DK1673091T3/da active
-
2006
- 2006-03-23 IL IL174536A patent/IL174536A/en unknown
- 2006-03-24 ZA ZA200602433A patent/ZA200602433B/en unknown
- 2006-04-20 NO NO20061744A patent/NO335813B1/no not_active IP Right Cessation
- 2006-04-21 IS IS8421A patent/IS2729B/is unknown
- 2006-10-13 HK HK06111293.5A patent/HK1090553A1/xx not_active IP Right Cessation
-
2010
- 2010-02-15 HR HR20100080T patent/HRP20100080T1/hr unknown
- 2010-02-16 CY CY20101100154T patent/CY1109814T1/el unknown
- 2010-06-11 US US12/813,917 patent/US20110046119A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL171977A (en) | Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same | |
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| CZ309247B6 (cs) | 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru | |
| TNSN06032A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
| TNSN06034A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| RU2006113366A (ru) | Терапевтическое лечение | |
| EA200800880A1 (ru) | Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции | |
| SE0401342D0 (sv) | Therapeutic compounds | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
| GB0130677D0 (en) | Medicaments and novel compounds | |
| NO20054714L (no) | Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom | |
| EA200000176A1 (ru) | Применение физиологически приемлемых соединений, солей и комплексов ванадия | |
| EA200801305A1 (ru) | Применение циклетанина и других фуропиридинов для лечения гипертензии с преобладанием систолического давления, изолированной систолической гипертензии, повышенного пульсового артериального давления и общей гипертензии | |
| PT1656131E (pt) | Utilização de betaína para tratar claudicação intermitente | |
| HK1077215A1 (en) | A pharmaceutical composition for treatment of acute myocardial infarction | |
| GEP201606538B (en) | Preoperative treatment of post operative pain | |
| RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
| DE60204694D1 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
| ATE404192T1 (de) | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration | |
| HUP0401798A2 (hu) | Rosuvastatin alkalmazása demencia előtti állapotokban használható gyógyszerkészítmény előállítására | |
| AU2003281257A8 (en) | A novel use of rapamycin and structural analogues thereof | |
| AR047154A1 (es) | Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol | |
| ATE447953T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160923 |